Five Israeli bio-techs at Israel’s MIXiii-Biomed 2018 are developing new therapies for “orphan” (rare) genetic diseases. They include ART Bioscience (Duchenne’s), Eloxx (cystinosis), SpliSense (Cystic Fibrosis), NewStem (Fragile X Syndrome) and Minovia (mitochondrial diseases).
https://www.israel21c.org/5-israeli-startups-seeking-cures-for-rare-genetic-diseases/
https://www.artbioscience.com/
http://www.integra-holdings.com/portfolio-items/splisense/
http://www.iati.co.il/company/3793/newstem
http://www.iati.co.il/company/3522/minovia-therapeutics
http://kenes-exhibitions.com/biomed/program/#day1